anti-VIP monoclonal antibodies

Anti-VIP monoclonal antibodies are humanized therapeutic agents designed to neutralize Vasoactive Intestinal Polypeptide (VIP), a 28-amino acid neuropeptide and hormone that exhibits potent immunosuppressive properties. In the microenvironment of hematological malignancies such as Acute Myeloid Leukemia (AML), VIP is frequently upregulated and serves as a co-inhibitory ligand that downregulates T cell anti-leukemia activity by signaling through its receptors, VPAC1 and VPAC2. By sequestering VIP, these monoclonal antibodies (including clones A6, C2, and D5) block this inhibitory pathway, thereby restoring and enhancing T cell-mediated anti-tumor responses. Developed by researchers at Emory University's Winship Cancer Institute, these antibodies have demonstrated superior in vitro T cell activation and improved survival in preclinical mouse models of myeloid sarcoma compared to peptide-based VIP receptor antagonists like ANT-308.

Other names

humanized anti-VIP monoclonal antibodiesanti-vasoactive intestinal polypeptide monoclonal antibodies